McKesson (MCK) Price & Analysis
MCK Stock Chart & Stats
- Day’s Range
- MXN 16,610.00 - MXN 17,700.00
- 52-Week Range
- MXN 12,269.41 - MXN 18,920.00
- Previous Close
- MXN 16,610.00
- Volume
- 0
- Average Volume (3M)
- 2
- Market Cap
- MXN 2.18T
- Enterprise Value
- MXN 99.45B
- Total Cash (Recent Filing)
- MXN 5.16B
- Total Debt (Recent Filing)
- MXN 11.70B
- Price to Earnings (P/E)
- 26.5
- Beta
- -0.05
- Next Earnings
- Nov 04, 2026
- EPS Estimate
- 201.35
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.35%
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
McKesson converts earnings into substantial cash, giving the business resilience despite its low-margin distribution model. Strong operating and free cash flow can fund technology, logistics, strategic investments, debt service, and shareholder returns over the next several quarters.
Broad-based Operating Growth
Raised guidance indicates that growth is supported across multiple operating areas rather than by a single product or customer group. Oncology, pharmaceuticals, and prescription technology each contribute expansion, improving business diversification and supporting durable earnings momentum.
Expansion Into Specialty Care
The planned Option Care transaction would deepen McKesson’s presence in specialty therapies and community-based infusion care, adding exposure to a growing healthcare delivery model. Its national footprint and technology-driven platform could broaden long-term service capabilities after closing.
Bears Say
Negative Shareholders’ Equity
Persistent negative equity is a structural balance-sheet weakness that reduces financial flexibility and makes conventional leverage signals harder to interpret. Although assets and liquidity are substantial, this capital structure leaves less protection against downturns, restructuring costs, or weaker cash generation.
Thin, Compressed Margins
McKesson’s distribution economics depend on very high volume because profitability per dollar of revenue is limited. Margin compression increases sensitivity to pricing, product mix, reimbursement, and execution, so modest operating pressure could have an outsized effect on earnings and cash returns.
MedSurg Profitability Pressure
The MedSurg segment is producing weaker profit conversion even while revenue grows, reflecting unfavorable product mix and administrative costs. Continued pressure would dilute consolidated operating leverage, while the separation and related financing may add complexity before the business reaches a more stable standalone profile.
McKesson News
MCK FAQ
What was McKesson’s price range in the past 12 months?
What is McKesson’s market cap?
When is McKesson’s upcoming earnings report date?
How were McKesson’s earnings last quarter?
Is McKesson overvalued?
Does McKesson pay dividends?
What is McKesson’s EPS estimate?
How many shares outstanding does McKesson have?
What happened to McKesson’s price movement after its last earnings report?
Which hedge fund is a major shareholder of McKesson?
What is the TipRanks Smart Score and how is it calculated?
McKesson Stock Smart Score
Company Description
McKesson
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Brian S. Tyler
- Employees
- 42,300
- Website
- www.mckesson.com
- Address
- 6555 State Highway 161, Irving, TX, 75039, US
McKesson (MCK) Earnings & Revenues
MCK Company Deck
MCK Earnings Call
Earnings Call SentimentPositive
The call communicated strong operational momentum: double-digit EPS growth, an 8% revenue increase to $105.4B, broad-based segment strength (notably Oncology & Multispecialty and North American Pharmaceuticals), improved gross profit and operating leverage, a raised full-year EPS guide, active capital returns (large buyback and dividend increase), and continued strategic progress on the MedSurg separation and tech/AI initiatives. Lowlights included a quarterly negative free cash flow readout (seasonal but improved vs prior year), a 20% decline in MedSurg operating profit, financing-related interest expense and GAAP remeasurement charges, and macro/regulatory uncertainties (WAC reductions, branded-to-generic conversions, 340B/IRA policy risks). Overall, the positive operational and financial beats and raised guidance materially outweigh the noted one-offs, financing costs, and policy risks.
View all MX:MCK earnings summariesMCK Net sales Breakdown
- 83.45% North American Pharmaceutical
- 12.00% Oncology & Multispecialty
- 1.44% Prescription Technology Solutions
- 2.85% Medical-Surgical Solutions
- 0.26% Other
MCK Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 2 | 3 |
| Technical Analysis | 5 | 2 | 2 |
| Moving Averages | 11 | 0 | 1 |